(Q37789267)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Treatment of pituitary neoplasms with temozolomide: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Michael D Cusimano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Bernd Walter Scheithauer

3

object named as

Bernd W Scheithauer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

9

Kalman Kovacs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Leon D Ortiz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ricardo Lloyd

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Queenie Lau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ricardo Gonzalez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Humberto Uribe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Eva Horvath

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

15 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

454-462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Use of temozolomide in aggressive pituitary tumors: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Management of aggressive pituitary adenomas: current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Recent clinical and pathophysiological advances in non-functioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Pathobiology of pituitary adenomas and carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Pituitary carcinoma: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Clinical review: Diagnosis and management of pituitary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Pituitary carcinoma: a clinicopathologic study of 15 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

A novel use of temozolomide in a patient with malignant prolactinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Treatment of Nelson's syndrome with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide in malignant gliomas: current use and future targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Chemical approaches to the discovery and development of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Current and future developments in the use of temozolomide for the treatment of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide for the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Malignant pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Methylation mechanisms in pituitary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Pituitary tumours: all silent on the epigenetics front

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Mechanisms of disease: temozolomide and glioblastoma--look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

Temozolomide: a novel treatment for pituitary carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25413

7 January 2021

Identifiers

DOI

10.1002/CNCR.25413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20845485%20AND%20SRC:MED&resulttype=core&format=json